Spero Therapeutics (NASDAQ:SPRO) Lowered to “Hold” at Zacks Investment Research

Zacks Investment Research cut shares of Spero Therapeutics (NASDAQ:SPRO) from a buy rating to a hold rating in a research note issued to investors on Friday, Zacks.com reports.

According to Zacks, “Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. “

Several other research analysts also recently weighed in on SPRO. TheStreet downgraded shares of Spero Therapeutics from a c- rating to a d+ rating in a research report on Monday, July 29th. HC Wainwright reissued a buy rating and issued a $27.00 target price on shares of Spero Therapeutics in a research report on Monday, August 12th. Cantor Fitzgerald reissued a buy rating and issued a $27.00 target price on shares of Spero Therapeutics in a research report on Thursday, May 9th. Finally, ValuEngine raised shares of Spero Therapeutics from a hold rating to a buy rating in a research report on Thursday, August 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. Spero Therapeutics currently has a consensus rating of Buy and a consensus price target of $20.60.

Shares of Spero Therapeutics stock traded up $0.57 during trading on Friday, hitting $10.14. The stock had a trading volume of 11,800 shares, compared to its average volume of 34,531. The stock has a 50 day simple moving average of $10.37 and a 200 day simple moving average of $11.54. The company has a market capitalization of $177.42 million, a PE ratio of -3.90 and a beta of 2.08. The company has a quick ratio of 17.48, a current ratio of 13.66 and a debt-to-equity ratio of 0.04. Spero Therapeutics has a 1 year low of $5.52 and a 1 year high of $14.48.

Spero Therapeutics (NASDAQ:SPRO) last released its earnings results on Thursday, August 8th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.10). The firm had revenue of $2.16 million during the quarter, compared to analysts’ expectations of $6.95 million. Spero Therapeutics had a negative return on equity of 33.84% and a negative net margin of 321.37%. As a group, equities analysts expect that Spero Therapeutics will post -2.94 earnings per share for the current fiscal year.

Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. boosted its holdings in shares of Spero Therapeutics by 5.7% during the fourth quarter. BlackRock Inc. now owns 393,630 shares of the company’s stock worth $2,421,000 after purchasing an additional 21,161 shares during the period. Virtu Financial LLC acquired a new stake in Spero Therapeutics in the first quarter valued at approximately $134,000. Bank of New York Mellon Corp lifted its stake in Spero Therapeutics by 31.9% in the fourth quarter. Bank of New York Mellon Corp now owns 36,716 shares of the company’s stock valued at $226,000 after acquiring an additional 8,888 shares during the last quarter. Northern Trust Corp lifted its stake in Spero Therapeutics by 1.1% in the fourth quarter. Northern Trust Corp now owns 96,833 shares of the company’s stock valued at $595,000 after acquiring an additional 1,038 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Spero Therapeutics by 4.4% in the fourth quarter. Geode Capital Management LLC now owns 91,842 shares of the company’s stock valued at $564,000 after acquiring an additional 3,876 shares during the last quarter. Institutional investors and hedge funds own 46.75% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.

Read More: What is Cost of Goods Sold (COGS)?

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.